Here, we engineered two FMD viruses with histidine residues inserted into or fused to the FMDV capsid. Both 6xHis viruses exhibited growth kinetics, plaque morphologies and antigenic characteristics similar to wild-type virus. The 6xHis tag allowed one-step purification of the mutant virions by Co2+ affinity columns. Electron microscopy and biochemical assays showed that the 6xHis FMDVs readily assembled into antigen: adjuvant complexes in solution, by conjugating with Ni2+-chelated nanolipoprotein and monophosphoryl lipid A adjuvant (MPLA:NiNLP). Animals Immunized with the inactivated 6xHis-FMDV:MPLA:NiNLP vaccine acquired enhanced protective immunity against FMDV challenge compared to virions alone. Induction of anti-6xHis and anti-FMDV neutralizing antibodies in the immunized animals could be exploited in the differentiation of vaccinated from infected animals needed for the improvement of FMD control measures. The novel marker vaccine/nanolipid technology described here has broad applications for the development of distinctive and effective immune responses to other pathogens of importance.
|Original language||English (US)|
|Number of pages||12|
|State||Published - Aug 1 2016|
Bibliographical noteFunding Information:
Funding for the research detailed in this manuscript was provided through Congressionally allocated dollars for the Agricultural Research Service of the United States Department of Agriculture . Specifically, CRIS projects no. 1940-32000-057-00D , Agricultural Research Service (ARS), U.S. Department of Agriculture (Dr. Elizabeth Rieder).
- 6xHis Tag
- FMD vaccine
- Nanolipoprotein adjuvants